Our data suggests that myeloid-high, stroma-enriched (Fig. 6D), neoantigen-depleted tumor regions historically experienced a cytotoxic T cell response, which prompted the selection of tumor clones losing neoantigens and/or HLA/CDKN2A/B. This evidence concerns the gene CDKN2A and neoplasm.